Uprosertib - Novartis Oncology

Drug Profile

Uprosertib - Novartis Oncology

Alternative Names: GSK-2141795; GSK-2141795C; GSK-795; UPB 795

Latest Information Update: 06 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Dana-Farber Cancer Institute; National Cancer Institute (USA); National Comprehensive Cancer Network; Novartis Oncology; University of California at San Francisco
  • Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Endometrial cancer; Malignant melanoma; Multiple myeloma; Uveal melanoma
  • No development reported Lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 31 Jul 2018 Uprosertib licensed to Laekna Therapeutics worldwide
  • 24 Jun 2018 Biomarkers information updated
  • 03 Dec 2016 Efficacy data from a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top